Search | Clinical Trials Finder

Conditions: ADHD, Attention Deficit Hyperactivity Disorder
Interventions: Other; Behavioral
Lead sponsor: Hugo W. Moser Research Institute at Kennedy Krieger, Inc.; Other
Eligibility: 12 Years to 17 Years
Enrollment: 312 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Conduct Disorder, Depression, Anxiety
Interventions: Animal-assisted intervention; Behavioral
Lead sponsor: Wayne State University; Other
Eligibility: 14 Years to 17 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Mount Clemens, Michigan

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Centanafadine; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 9 Years to 12 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: ADHD
Interventions: SPD489, Placebo; Drug · Other
Lead sponsor: Shire; Industry
Eligibility: 13 Years to 17 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 6
States / cities: Little Rock, Arkansas • Bradenton, Florida • Overland Park, Kansas + 3 more

Conditions: Bipolar Disorder, Attention Deficit Disorder With Hyperactivity, Attention Deficit Disorder Without Hyperactivity, Generalized Anxiety Disorder, Healthy
Interventions: Not listed
Lead sponsor: Bradley Hospital; Other
Eligibility: 7 Years to 17 Years
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2018
U.S. locations: 1
States / cities: East Providence, Rhode Island

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: TC-5619-238 5mg, TC-5619-238 25mg, Placebo; Drug
Lead sponsor: Targacept Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 14
States / cities: Beverly Hills, California • National City, California • Colorado Springs, Colorado + 9 more

Conditions: ADHD, Obsessive Compulsive Disorder (OCD), Healthy Volunteer
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 10 Years to 17 Years
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: ADHD
Interventions: Behavioral Parent Training (BPT); Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 4 Years to 11 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: New York, New York • Cincinnati, Ohio

Conditions: Attention Deficit Disorder With Hyperactivity, Asthma, COPD, Breast Cancer, Coronary Artery Disease, Congestive Heart Failure, Diabetes, Glaucoma, Hemophilia, Hypertension, Hyperthyroidism, Hypothyroidism, Myasthenia Gravis, Osteoporosis, Osteopenia, Renal Failure, Renal Insufficiency, Sickle Cell Disease, Stroke
Interventions: MAPLE; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder
Interventions: Methylphenidate, Placebo; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 8 Years to 21 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Attention Deficit Hyperactivity Disorder (ADHD)
Interventions: SPN-810 (18 mg), SPN-810 (36 mg), Placebo; Drug
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 28
States / cities: Rogers, Arkansas • Culver City, California • Glendale, California + 22 more

Conditions: Attention Deficit Hyperactivity Disorder (ADHD)
Interventions: Behavioral assessment and NAT EEG tests; Other
Lead sponsor: Think Now Incorporated; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: ADHD
Interventions: Placebo, 100mg SPN-812, 200mg SPN-812; Drug
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 477 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 7
States / cities: Dothan, Alabama • Hialeah, Florida • Meridian, Idaho + 4 more

Conditions: Attention Deficit Disorder With Hyperactivity
Interventions: Methylphenidate; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 3 Years to 5 Years
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 6
States / cities: Irvine, California • Los Angeles, California • Baltimore, Maryland + 2 more

Conditions: ADHD
Interventions: ADHD Group Curriculum; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 6 Years to 18 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Attention Deficit Disorder With Hyperactivity
Interventions: Atomoxetine Hydrochloride, placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: ADHD
Interventions: Classroom Behavior Support (CBS) Condition, Standard Problem Solving Consultation; Behavioral
Lead sponsor: Ohio University; Other
Eligibility: 5 Years to 12 Years
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Athens, Ohio

Conditions: Attention Deficit Disorder With Hyperactivity
Interventions: Atomoxetine, Placebo, Parent Training; Drug · Behavioral
Lead sponsor: University of Nebraska; Other
Eligibility: 5 Years to 6 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 3
States / cities: Omaha, Nebraska • New York, New York • Durham, North Carolina

Conditions: Attention-Deficit/Hyperactivity Disorder (Combined-subtype)
Interventions: Working memory training, Functional magnetic resonance imaging (fMRI); Behavioral · Device
Lead sponsor: Hartford Hospital; Other
Eligibility: 13 Years to 17 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Attention Deficit/Hyperactivity Disorder
Interventions: Vyvanse; Drug
Lead sponsor: Kimberley Lakes; Other
Eligibility: 6 Years to 12 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Irvine, California

Conditions: ADHD
Interventions: Potassium Gluconate Oral Capsule, Placebo oral capsule; Drug
Lead sponsor: AlkaliDx, Inc.; Industry
Eligibility: 13 Years to 49 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Voorhees Township, New Jersey

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: LDX Treatment; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Attention Deficit Hyperactivity Disorder, Schizophrenia, Attention Deficit Disorder With Hyperactivity
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 3 Years to 120 Years
Enrollment: 4,276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1990
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Impulsive Aggression Comorbid With ADHD
Interventions: SPN-810, Placebo; Drug
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 27
States / cities: Dothan, Alabama • Los Angeles, California • Santa Ana, California + 24 more

Search by objective public record fields.

Adolescent Changes in Brain and Behavior in Boys and Girls With ADHD

Randomized Control Trial of an Animal-Assisted Intervention With Adjudicated Youth

Open-label, Single-dose Trial to Assess the Pharmacokinetics of Centanafadine Extended-release Capsules in Pediatric Participants With Attention-deficit Hyperactivity Disorder (ADHD)

Safety and Efficacy of SPD489 in Adolescent Subjects Aged 13-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)

Brain Imaging and Computer Games in Children With Either Bipolar Disorder, ADHD, Anxiety or Healthy Controls

Safety & Efficacy of TC-5619 in Adults With Inattentive-predominant Attention Deficit/Hyperactivity Disorder (ADHD)

Role of Theta Frequency Oscillations in Proactive and Reactive Control Processes in Youth With Attention Deficit Hyperactivity Disorder (ADHD) and Obsessive Compulsive Disorder (OCD)

Telehealth BPT in DBP Practice

Study of an Intervention to Improve Problem List Accuracy and Use

Eye Tracking as a Predictor of Methylphenidate Response in Autism With ADHD

Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1)

Neurophysiological Attention Test (NAT) for Objective Assessment of Attention Deficit Hyperactivity Disorder (ADHD)

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Children With ADHD

Treatment of Attention Deficit Hyperactivity Disorder in Preschool-Age Children (PATS)

Exploring the Group Visit Model for Pediatric ADHD Management in the Medical Home

A Functional Outcomes Study With Atomoxetine-Hydrochloride and Placebo in Adults With Attention-Deficit/Hyperactivity Disorder

Classroom Behavior Support (CBS) Project

Atomoxetine for Treating Attention Deficit Hyperactivity Disorder in Young Children

Effect of Working Memory Training on ADHD Brain Function

The Effects of Vyvanse(TM) on Brain Hemodynamics and Reading

Single-dose Potassium Supplementation in Patients With ADHD for Whom the Anesthetic Lidocaine is Ineffective

Effectiveness and Duration of Effect of Open Treatment in Attention Deficit Hyperactivity Disorder (ADHD) Patients Treated With Lisdexamfetamine Dimesylate(Vyvanse)

Brain Imaging of Childhood Onset Psychiatric Disorders, Endocrine Disorders and Healthy Volunteers

A Study to Evaluate the Efficacy and Safety of SPN-810 as Adjunctive Therapy in Children With Impulsive Aggression Comorbid With Attention-Deficit/Hyperactivity Disorder (ADHD)